Cytokinetics
CYTK
343 hedge funds and large institutions have $7.34B invested in Cytokinetics in 2024 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 156 increasing their positions, 92 reducing their positions, and 86 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 156 | Existing positions reduced: 92
54% more call options, than puts
Call options by funds: $199M | Put options by funds: $130M
3.79% more ownership
Funds ownership: 114.35% → 118.14% (+3.8%)
9% less funds holding in top 10
Funds holding in top 10: 22 → 20 (-2)
11% less capital invested
Capital invested by funds: $8.26B → $7.34B (-$919M)
12% less funds holding
Funds holding: 390 → 343 (-47)
50% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 86
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$276M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$213M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$182M |
| 4 |
BlackRock
New York
|
+$136M |
| 5 |
State Street
Boston,
Massachusetts
|
+$122M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$53M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$49.6M |
| 3 |
Millennium Management
New York
|
-$48.9M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$36.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$34.6M |
CYTK Hedge Fund Activity: Q2 2024 in Review
343 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q2 2024, worth a combined $7.34B — down 11% from $8.26B a quarter earlier.
Sellers outnumbered buyers: 86 funds closed out of CYTK and 43 opened new positions — a net loss of 43 holders — while 92 trimmed existing stakes and 156 added.
The largest buyer was Darwin Global Management, opening a new position worth an estimated $276M. The largest seller was Marshall Wace, cutting an estimated $53M.
- 343 institutional investors held Cytokinetics (CYTK) as of Q2 2024, down from 390 in Q1 2024.
- Funds reported $7.34B of Cytokinetics stock for Q2 2024, down 11% quarter-over-quarter.
- 43 funds opened new Cytokinetics positions in Q2 2024 and 86 closed out, a net change of -43 holders.
- The largest Cytokinetics buyer in Q2 2024 was Darwin Global Management, an estimated $276M added.
- The largest Cytokinetics seller in Q2 2024 was Marshall Wace, an estimated $53M sold.
Based on aggregated 13F filings for Q2 2024.